Patents by Inventor Ulla Wewer

Ulla Wewer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-ADAM12 antibodies for the treatment of cancer
    Publication number: 20160208016
    Abstract: The present disclosure concerns monoclonal antibodies directed to the pro-domain of ADAM 12 and their use in the treatment of cancer.
    Type: Application
    Filed: August 29, 2014
    Publication date: July 21, 2016
    Inventors: Reidar Albrechtsen, Camilla Fröhlich, Ulla Wewer
  • ADAM12, a novel marker for abnormal cell function
    Publication number: 20060134654
    Abstract: The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum.
    Type: Application
    Filed: May 18, 2005
    Publication date: June 22, 2006
    Inventors: Ulla Wewer, Bent Norgaard-Pedersen, Michael Christiansen, Jennie Laigaard, Camilla Frohlich, Kevin Spencer